Blood test could predict metastasis risk in melanoma

Scientists at Yale University have identified a set of plasma biomarkers that could reasonably predict the risk of metastasis among patients with melanoma, according to findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"The rate at which melanoma is increasing is dramatic, and there is a huge number of patients under surveillance," said Harriet Kluger, M.D., associate professor of medicine at Yale University School of Medicine. "Our current method of surveillance includes periodic imaging, which creates huge societal costs."

Melanoma is the fifth most common cancer in men and the seventh most common cancer in women. It is estimated that 68,130 people in the United States were diagnosed in 2010, and 8,700 died. With proper screening, melanoma can often be caught early enough to be removed with surgery, and mortality typically comes when the cancer metastasizes. The risk of varies from less than 10 percent for those with stage 1A melanoma, to as high as 70 percent with stage 3C.

Patients with melanoma are typically subjected to a combination of imaging tests, blood tests and physical examinations, but there is no clear consensus on how often these tests should occur or how reliable they are.

Kluger and colleagues tested the plasma of 216 individuals, including 108 patients with and 108 patients with stage 1 or 2 disease. They identified seven plasma biomarkers: CEACAM, ICAM-1, osteopontin, MIA, GDF-15, TIMP-1 and S100B.

All of these were higher in patients with metastatic than patients with early-stage disease. In fact, 76 percent of patients with early-stage disease had no elevations at all whereas 83 percent of metastatic patients had elevations of at least one marker. Researchers calculated that the area under the curve, a measure of the test's reliability, was 0.898. Area under the curve calculations rate from .5 to 1, with 1 being optimal and .5 being useless.

"This finding will need to be confirmed prospectively before it is used in the clinic, but it shows that such testing is possible," said Kluger.

Related Stories

New combination therapy safe, promising for melanoma patients

Jun 01, 2008

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American ...

Protein Markers Predict Risk of Melanoma Recurrence

Dec 03, 2009

(PhysOrg.com) -- A new prognostic tool that can determine the risk of recurrence in melanoma patients has been developed by researchers at Yale Cancer Center. The technology, based on five proteins expressed in melanoma tissue, ...

Late-stage melanoma results in economic burden

Mar 15, 2010

In an article published in the March 2010 Archives of Dermatology, researchers report that in the United States, melanoma treatment in late stages of the disease is of significant cost in the population 65 years and older. ...

Recommended for you

New breast cancer imaging method promising

1 hour ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

1 hour ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

3 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

7 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments